Impact of the anti-inflammatory agent bindarit on the chemokinome: selective inhibition of the monocyte chemotactic proteins.

@article{Mirolo2008ImpactOT,
  title={Impact of the anti-inflammatory agent bindarit on the chemokinome: selective inhibition of the monocyte chemotactic proteins.},
  author={Massimiliano Mirolo and Marco Fabbri and Marina Sironi and Annunciata Vecchi and Angelo Guglielmotti and Giorgina Mangano and G. Biondi and Massimo Locati and Alberto Mantovani},
  journal={European cytokine network},
  year={2008},
  volume={19 3},
  pages={
          119-22
        }
}
Bindarit is an indazolic derivative that is devoid of any immunosuppressive effects and has no effect on arachidonic acid metabolism. However, it has been proved to have anti-inflammatory activity in a number of experimental diseases, including pancreatitis, arthritis, and lupus nephritis. This therapeutic effect has been associated with its ability to interfere selectively with monocyte recruitment, although the underlying molecular mechanisms are unknown. Here we comprehensively examine the… Expand
Bindarit: an anti-inflammatory small molecule that modulates the NFκB pathway.
TLDR
This work investigates the effect of bindarit on the LPS-induced production of inflammatory cytokines in both a mouse leukaemic monocyte-macrophage cell line and bone marrow derived macrophages and concludes thatbindarit acts on a specific subpopulation of NFκB isoforms and selects its targets wihtin the wholeNFκB inflammatory pathway. Expand
The anti-inflammatory agent bindarit inhibits neointima formation in both rats and hyperlipidaemic mice
TLDR
It is demonstrated that bindarit is effective in reducing neointima formation in both non-hyperlipidaemic and hyperlipIDAemic animal models of vascular injury by a direct effect on VSMC proliferation and migration and by reducing neointedimal macrophage content. Expand
The monocyte chemotactic protein synthesis inhibitor bindarit prevents mesangial cell proliferation and extracellular matrix remodeling.
TLDR
The data confirm the important role of MCP-1/CCL2 synthesis in mesangial cell dysfunction and support the potential of therapeutic intervention targeting this chemokine in kidney disease. Expand
Bindarit, an anti-inflammatory agent, reduces neointimal hyperplasia in animal models of vascular injury
TLDR
The effect of bindarit on human coronary smooth muscle cells activation is investigated, drawing attention to the phenotypic modulation process, focusing on contractile proteins expression as well as proliferation and migration. Expand
The CCL2 synthesis inhibitor bindarit targets cells of the neurovascular unit, and suppresses experimental autoimmune encephalomyelitis
TLDR
Results suggest that bindarit might prove an effective treatment for neuroinflammation in both preventative and therapeutic ways. Expand
Targeting monocyte chemotactic protein-1 synthesis with bindarit induces tumor regression in prostate and breast cancer animal models
TLDR
Overall, the data indicate that bindarit is a good candidate for new therapies against prostate and breast tumorigenesis, with an action through impairment of inflammatory cell responses during formation of the tumor–stroma niche microenvironment. Expand
Effects of MCP-1 Inhibition by Bindarit Therapy in a Rat Model of Polycystic Kidney Disease
TLDR
Although bindarit did not prevent renal cyst growth, it limited interstitial inflammation and renal dysfunction and reduced proteinuria in PKD, and could be considered a therapeutic intervention complementary to therapies specifically acting to block renal Cyst growth. Expand
Amelioration of alphavirus-induced arthritis and myositis in a mouse model by treatment with bindarit, an inhibitor of monocyte chemotactic proteins.
TLDR
The data support the use of inhibitors of MCP production in the treatment of arthritogenic alphavirus syndromes and suggest that bindarit may be useful in treating RRVD and other alphvirus-induced arthritis in humans. Expand
Effects of the MCP-1 synthesis inhibitor bindarit on tumorigenesis and inflammatory markers in the C3(1)/SV40Tag mouse model of breast cancer.
TLDR
Results show that tumor multiplicity in the C3(1)/SV40Tag mouse model of breast cancer is reduced by bindarit, however these effects are independent of changes in plasma levels of MCP-1 and IL-6, but may be related to the attenuated expression of M CP-1 along with several inflammatory mediators and macrophage markers within the tumor. Expand
Renal accumulation of macrophages in experimental polycystic kidney disease is reduced by bindarit
TLDR
B bindarit’s effects on the evolution of PKD in PCK rats and on the activity of the drug in cultured podocytes are described to explain its antiproteinuric effect. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 18 REFERENCES
A small synthetic molecule capable of preferentially inhibiting the production of the CC chemokine monocyte chemotactic protein-1.
TLDR
It is suggested that bindarit's beneficial effects in models of joint and kidney inflammation are related to its anti-MCP-1 action and it is possible to selectively and differentially regulate chemokines by targeting their production with small synthetic molecules. Expand
Treatment with bindarit, a blocker of MCP-1 synthesis, protects mice against acute pancreatitis.
TLDR
This treatment significantly protected mice against acute pancreatitis as evident by attenuated hyperamylasemia neutrophil sequestration in the pancreas (pancreatic MPO activity), and pancreatic acinar cell injury/necrosis on histological examination of Pancreas sections. Expand
Amelioration of rat adjuvant arthritis by therapeutic treatment with bindarit, an inhibitor of MCP-1 and TNF-α production
TLDR
Results obtained indicate that bindarit beneficial effects in experimental arthritis are correlated to MCP-1 and TNF-α inhibition and suggest that the control of cytokines and chemokines production can have considerable relevance as regards strategies for the treatment of chronic inflammatory diseases. Expand
The MCP/eotaxin subfamily of CC chemokines.
TLDR
The focus is on the monocyte chemotactic proteins and eotaxin which, on a structural basis, can be considered as a CC chemokine subfamily, whereas fractalkine (CX3C) and lymphotactin (C) are unique relatives. Expand
The molecular biology of leukocyte chemoattractant receptors.
  • P. Murphy
  • Biology, Medicine
  • Annual review of immunology
  • 1994
TLDR
Surprising developments suggest that in addition to leukocyte-mediated inflammation, the chemokines may also be involved in erythrocyte function and, through molecular mimicry, in microbial pathogenesis. Expand
A new protein antidenaturant agent, bindarit, reduces secondary phase of adjuvant arthritis in rats.
TLDR
Assessment of both electrophoretic and quantitative changes suggests that the reduction of albumin during inflammation is due, at least in part, to a denaturation of native albumin, which loses its electrophic mobility. Expand
Chronic inflammatory response in the rat can be blocked by bindarit.
TLDR
The addition of bindarit and indomethacin were able to reduce the concentration of alpha 2-macroglobulin as well as the Con A-reactivity of various proteins to normal level 37 days following treatment, while chronic inflammation did not induce significant changes in both the clusterin and testibumin concentrations. Expand
Chemokines and their receptors: drug targets in immunity and inflammation.
TLDR
The role of chemokines in health and diseases is examined, strategies to target the chemokine system are discussed, and several promising drugs are currently being tested in late-stage clinical trials. Expand
Allosteric inhibitors of chemoattractant receptors: opportunities and pitfalls.
TLDR
Allosteric inhibitors pose new questions concerning different phases in drug discovery and pharmacological characterization, including the identification of appropriate screening tests, the evaluation of inhibitory effects on different signaling pathways and the implications of agonist- and signaling pathway-dependent inhibition for overall in vivo efficacy. Expand
Molecules and structures involved in the adhesion of natural killer cells to vascular endothelium
TLDR
The identification of molecules and microanatomical structures involved in the interaction of NK cells with EC may provide a better understanding of the regulation of NK cell recruitment from blood, their extravasation, and their migration to tissues. Expand
...
1
2
...